KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Research & Development: 2009-2025

Historic Research & Development for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $87.8 million.

  • Acadia Pharmaceuticals' Research & Development rose 31.86% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $344.8 million, marking a year-over-year increase of 28.05%. This contributed to the annual value of $303.2 million for FY2024, which is 13.76% down from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Research & Development stood at $87.8 million, which was up 12.67% from $78.0 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Research & Development high stood at $157.0 million for Q3 2023, and its period low was $56.9 million during Q2 2021.
  • Moreover, its 3-year median value for Research & Development was $76.2 million (2024), whereas its average is $81.7 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Research & Development soared by 126.17% in 2022, and later tumbled by 57.57% in 2024.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Research & Development stood at $66.9 million in 2021, then increased by 13.14% to $75.7 million in 2022, then dropped by 11.88% to $66.7 million in 2023, then skyrocketed by 50.93% to $100.7 million in 2024, then surged by 31.86% to $87.8 million in 2025.
  • Its Research & Development stands at $87.8 million for Q3 2025, versus $78.0 million for Q2 2025 and $78.3 million for Q1 2025.